相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
F. Ravandi et al.
LEUKEMIA (2014)
Inflammation-Induced NFATc1-STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by KrasG12D
Sandra Baumgart et al.
CANCER DISCOVERY (2014)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
Sharyn D. Baker et al.
CLINICAL CANCER RESEARCH (2013)
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Michael R. Grunwald et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
Ashu Kumari et al.
BLOOD (2012)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Disruption of a Nuclear NFATc2 Protein Stabilization Loop Confers Breast and Pancreatic Cancer Growth Suppression by Zoledronic Acid
Shiv K. Singh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia
Shuiying Hu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
Mark A. Gregory et al.
CANCER CELL (2010)
Bench to Bedside Targeting of FLT3 in Acute Leukemia
Keith W. Pratz et al.
CURRENT DRUG TARGETS (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K. W. Pratz et al.
LEUKEMIA (2010)
NFAT, immunity and cancer: a transcription factor comes of age
Martin R. Mueller et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
NFAT proteins: emerging roles in cancer progression
Maria Mancini et al.
NATURE REVIEWS CANCER (2009)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia
Benjamin H. Lee et al.
CANCER CELL (2007)
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia
Hind Medyouf et al.
NATURE MEDICINE (2007)
Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34+ cells:: regulation of Fas ligand gene expression in megakaryocytes
Alexander Kiani et al.
EXPERIMENTAL HEMATOLOGY (2007)
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT 5 pathway activation
Ying Wang et al.
BLOOD (2007)
Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway
Malte Buchholz et al.
EMBO JOURNAL (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Constitutive NF-κB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival
LV Pham et al.
BLOOD (2005)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
NFAT proteins: Key regulators of T-cell development and function
F Macian
NATURE REVIEWS IMMUNOLOGY (2005)
The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas
T Marafiot et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Use of cyclosporine in hematopoietic cell transplantation
WJ Hogan et al.
TRANSPLANTATION PROCEEDINGS (2004)
Expression and regulation of NFAT (nuclear factors of activated T cells) in human CD34+ cells:: down-regulation upon myeloid differentiation
A Kiani et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
R Zheng et al.
BLOOD (2004)
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
RB Walter et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD4+ T cells
CM Porter et al.
JOURNAL OF IMMUNOLOGY (2002)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
AF List et al.
BLOOD (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
ML Linenberger et al.
BLOOD (2001)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
分享论文
